Stocks › SBFM
Sunshine Biopharma Inc.
SBFM·Nasdaq·
United States·USD
United States·USD$0.40
-0.02 (-5.28%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
SBFM
Sunshine Biopharma Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
SBFMS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of SBFM by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Roger WilliamsHouse · R · TX |
SBFMSunshine Biopharma Inc. · Stock |
Purchase $1,001 - $15,000 |
Jun 12, 2024 | Jun 30, 2022 | Filing ↗ |
Whale Activity
Position changes in SBFM reported for 2026-06-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed1
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| Citadel Advisors LLC | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by SBFM insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
54 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| NATAN DAVIDDirector | Grant / award | +100.0K | $0.00 | $0 | Apr 14, 2026 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director · 10% owner | Purchase | +100.0K | $0.10 | $10K | Mar 4, 2024 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director · 10% owner | Purchase | +20.0K | n/c | — | Feb 8, 2024 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary | Purchase | +30.0K | $0.76 | $23K | Nov 30, 2022 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary | Purchase | +25.0K | $1.22 | $31K | Jun 3, 2022 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Disposition to issuer | −990.0K | $0.10 | $99K | Feb 18, 2022 | Form 4 ↗ |
| MERZOUKI ABDERRAZZAKChief Operating Officer · Director | Grant / award | +20.0M | $0.00 | $0 | Jan 6, 2021 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +20.0M | $0.00 | $0 | Jan 6, 2021 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +20.0M | $0.00 | $0 | Jan 6, 2021 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +500.0K | $0.10 | $50K | Jun 17, 2020 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | −323.7K | $0.00 | $0 | Dec 31, 2019 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Other | +323.7K | $0.00 | $0 | Dec 31, 2019 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +1.3M | $0.00 | $0 | Dec 19, 2019 | Form 4 ↗ |
| MERZOUKI ABDERRAZZAKChief Operating Officer · Director | Grant / award | +1.3M | $0.00 | $0 | Dec 19, 2019 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +1.3M | $0.00 | $0 | Dec 19, 2019 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +1.1M | $0.00 | $0 | Oct 20, 2019 | Form 4 ↗ |
| MERZOUKI ABDERRAZZAKChief Operating Officer · Director | Grant / award | +1.1M | $0.00 | $0 | Oct 20, 2019 | Form 4 ↗ |
| Slilaty Steve N.Chief Executive Officer · Director | Grant / award | +1.1M | $0.00 | $0 | Oct 20, 2019 | Form 4 ↗ |
| Sebaaly CamilleCFO/Secretary · Director | Grant / award | +550.0K | $0.00 | $0 | Sep 11, 2019 | Form 4 ↗ |
| Sebaaly CamilleSecretary · Director · 10% owner | Grant / award | +11.0M | $0.00 | $0 | Sep 11, 2019 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding SBFM · SEC Form N-PORT
No mutual fund or ETF has reported SBFM in an N-PORT filing in the last seven months.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Alta Partners LLCSCHEDULE 13G/A · passive (13G) · 200.0K shares4.9%
Oct 5, 2026 · ↗ - L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 111.5K shares5.0%
Aug 14, 2026 · ↗ - Intracoastal Capital LLCSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
Aug 13, 2026 · ↗ - Daniel B. AsherSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
Aug 13, 2026 · ↗ - Mitchell P. KopinSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
Aug 13, 2026 · ↗ - Alta Partners LLCSCHEDULE 13G · passive (13G) · 200.0K shares8.6%
Jul 8, 2026 · ↗ - L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G · passive (13G) · 1.0M shares5.8%
May 22, 2026 · ↗ - Bigger MichaelSCHEDULE 13G · passive (13G) · 1.6M shares9.5%
May 21, 2026 · ↗ - District 2 Holdings LLCSCHEDULE 13G · passive (13G) · 805.0K shares4.7%
May 21, 2026 · ↗ - District 2 GP LLCSCHEDULE 13G · passive (13G) · 805.0K shares4.7%
May 21, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Sunshine Biopharma Inc. as client
No lobbying filings found naming Sunshine Biopharma Inc. as the client.
Government Contracts
Federal awards to Sunshine Biopharma Inc. · USAspending
No federal contract awards found for Sunshine Biopharma Inc..
U.S. Patents
Recent USPTO applications naming Sunshine Biopharma Inc.
No USPTO patent applications found for Sunshine Biopharma Inc..
Annual Financials
From SBFM's 10-K filings · XBRL
No annual XBRL figures on record for SBFM. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-10Reverse splitJun 1, 2026
- 1-for-20Reverse splitAug 8, 2024
- 1-for-100Reverse splitApr 17, 2024
- 1-for-20Reverse splitFeb 1, 2019
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.07Shareholder voteSep 16, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 11, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeAug 28, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 3, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementJul 20, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsMay 19, 2026
EDGAR ↗
About Sunshine Biopharma Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersFORT LAUDERDALE, FL
IncorporatedCO
SEC CIK0001402328 ↗
Former namesSunshine Biopharma, Inc, Mountain West Business Solutions, Inc, mountain west business solutions,inc